Chronic inflammation increases the risk of cardiovascular disease in patients with rheumatoid arthritis;Kronisk inflammation øger risikoen for kardiovaskulær sygdom hos patienter med reumatoid artritis

Ugeskrift for Laeger

Volumn 168, Issue 39, 2006, Pages 3304-3308

  Troelsen, Lone N ^a   Jacobsen, Søren ^a  

^a University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; HUMAN; MORBIDITY; MORTALITY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; RISK FACTORS;

EID: 33749265109     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002;46:862-73.
2. Goodson NJ, Marks J, Lunt M et al. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with an onset in the 1980's and 1990's. Ann Rheum Dis 2005;64:1595-601.
3. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
4. Del Rincon I, Williams K, Stern MP et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
5. Gonzalez-Juanatey C, Llorca J, Testa A et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 2003;82:407-13.
6. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.
7. Nagata-Sakurai M, Inaba M, Goto H et al. Inflammation and bone resorption as independent factors of accelerated arterial wall thickening in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:3061-67.
8. Vaudo G, Marchesi S, Gerli R et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31-5.
9. Maradit-Kremers H, Nicola PJ, Crowson CS et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
10. WallbergJonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 1997;24:445-51.
11. Kremers HM, Nicola PJ, Crowson CS et al. Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 2004;50:3450-7.
12. Sattar N, McCarey DW, Capell H et al. Explaining how "high- grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
13. Hernanz A, Plaza A, Martin-Mola E et al. Increased plasma levels of homocysteine and other thiol compounds in rheumatoid arthritis women. Clin Biochem 1999;32:65-70.
14. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-65.
15. Hansson GK. Mechanisms of disease - inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
16. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
17. Soderlin MK, Nieminen P, Hakala M. Functional status predicts mortality in a community based rheumatoid arthritis population. J Rheumatol 1998;25:1895-9.
18. Turesson C, O'Fallon WM, Crowson CS et al. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 2002;29:62-7.
19. Gerli R, Schillaci G, Giordano A et al. CD4+CD28-T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 2004;109:2744-8.
20. Swanberg M, Lidman O, Padyukov L et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005;37:486-94.
21. Szmitko P.E., Verma S. C-reactive protein and statins: IL-8 as a molecular link? Clin Sci (lon) 2005;108:493-5
22. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-9.
23. Luchetti MM, Piccinini G, Mantovani A et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol 2000;119:196-202.
24. Napoleone E, Di Santo A, Peri G et al. The long pentraxin PTX3 up-regulates tissue factor in activated monocytes: another link between inflammation and clotting activation. J Leukoc Biol 2004;76:203-9.
25. Ohlenschlaeger T, Garred P, Madsen HO et al. Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 2004;351:260-7.
26. Jacobsen S, Madsen HO, Klarlund M et al. The influence of mannose binding lectin polymorphisms on disease outcome in early polyarthritis. J Rheumatol 2001;28:935-42.
27. Garred P, Madsen HO, Marquaet H et al. Two edged role of mannose binding lectin in rheumatoid arthritis: a cross sectional study. J Rheum 2000;27:26-34.
28. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004;202:250-65.
29. Diamant M, Tushuizen ME, Sturk A et al. Cellular microparticles: new players in the field of vascular disease? Eur J Clin Invest 2004;34:392-401.
30. Martínez MC, Tesse A, Zobairi et al. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005;289:1106-14.
31. Knijff-Dutmer EAJ, Koerts J, Nieuwland R et al. Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 2002;46:1498-503.
32. Berckmans RJ, Nieuwland R, Tak PP et al. Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 2002;46:2857-66.
33. McEntegart A, Capell HA, Creran D et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001;40:640-4.
34. Gonzalez-Juanatey C, Gonzalez-Gay MA. Long-term rheumatoid arthritis and endothelial dysfunction. Atherosclerosis 2004;176:197-8.
35. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
36. Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs - a population-based case-control study. Arch Intern Med 2005;165:978-84.
37. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Medicine 2005;352:20-8.
38. McCarey DW, McInnes LB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004;363:2015-21.
39. Hermann F, Forster A, Chenevard R et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005;45:461-4.